Dose-response study (72h-IC50) validated that KRAS-mutant CRC cells were more sensitive to R-IMPP and PF-0644846 compared to 1CT and NCM460 normal colonic cell lines (Fig. 5H and Fig. S14). Here, KRAS is linked to colorectal carcinoma.